Amygdala Neurosciences
San Francisco, US · 1 known investors
Amygdala Neurosciences is a biopharmaceutical company developing oral medications to treat alcohol and substance use disorders by targeting the ALDH2 enzyme. The company addresses unmet clinical needs in addiction treatment through novel pharmacotherapies.
BiotechMedical Devices
Founders & leadership
CS
Chief Scientific Officer & FounderCSO & Founder
Investors · 1
In the news
- ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorderprnewswire.com · 2024
- News - Amygdala Neusciencesamygns.com · 2023
- Amygdala Neurosciences - 2025 Company Profile, Funding & Competitors - Tracxntracxn.com · 2021
- Amygdala Neurosciences Raises $5.6M in Financing - FinSMEsfinsmes.com · 2019
- Amygdala Neurosciences - Tech Company Profile - Gaebler.com Venture Capital Databasegaebler.com